title: US Food and Drug Administration approval overview in metastatic breast cancer.
authors.affiliation: US Food and Drug Administration, Silver Spring, MD 20993-0002, USA. patricia.cortazar@fda.hhs.gov
authors.forename: Patricia
authors.initials: P
authors.lastname: Cortazar
authors.forename: Robert
authors.initials: R
authors.lastname: Justice
authors.forename: John
authors.initials: J
authors.lastname: Johnson
authors.forename: Rajeshwari
authors.initials: R
authors.lastname: Sridhara
authors.forename: Patricia
authors.initials: P
authors.lastname: Keegan
authors.forename: Richard
authors.initials: R
authors.lastname: Pazdur
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017277:Drug Approval; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal